Efficacy and Safety of Il-17 Inhibitors in Moderate-To-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Moderate-to-severe plaque psoriasis is a chronic inflammatory disease with high prevalence that significantly impacts patients’ quality of life. In recent years, interleukin-17 inhibitors have emerged as one of the most effective biologic therapeutic options for the management of this condition. The aim of this study was to comprehensively evaluate the efficacy and safety of IL-17 inhibitors in patients with moderate-to-severe plaque psoriasis through a systematic review and narrative meta-analysis of the available literature. An exhaustive search was conducted in international electronic databases, identifying randomized controlled trials and observational studies evaluating secukinumab, ixekizumab, brodalumab, and bimekizumab. The results demonstrate that treatment with IL-17 inhibitors is associated with significant clinical improvement, evidenced by high rates of PASI 75, PASI 90, and PASI 100 responses, as well as rapid reduction of cutaneous inflammatory activity. In addition, a favorable safety profile was observed, with mostly mild to moderate adverse events and a low rate of treatment discontinuation, with mucocutaneous infections being the most frequently reported adverse event. Overall, the available evidence supports IL-17 inhibitors as a highly effective and safe therapeutic option for the treatment of moderate-to-severe plaque psoriasis, consolidating their role as a first-line alternative in the current management of this disease.